sovietknuckles

This mucosal/nasal vaccine is called MPV/S-2P and it is developed by the NIH's National Institute of Allergy and Infectious Diseases (NIAID). From a 2023 study:

A single dose of MPV/S-2P was highly immunogenic, and a second dose increased the magnitude and breadth of the mucosal and systemic anti-S antibody responses and increased levels of dimeric anti-S IgA in the airways.

Obviously don't dox yourself on Hexbear, but the phase 1 trial sites are:

so if you live near one of those, maybe you can participate.

They want to enroll 60 people, no clue how close they are to that goal

To try to enroll, contact them by phone or email.

The spray is called "Pathogen Capture and Neutralizing Spray" (PCANS) for now

This data suggest PCANS as a promising daily-use prophylactic against respiratory infections.

The study is paywalled, and the abstract doesn't list its ingredients beyond

The formulation consists of excipients identified from the FDA's Inactive Ingredient Database and Generally Recognized as Safe list to maximize efficacy for each step in the multi-modal approach.

Based on that description, its ingredients might not be very different from Covixyl, though it claims to be much more effective.

Edit: Apparently its already for sale, I included some details in a comment

Evangelical Christians are the largest pro-Israel lobby in the US

Mucosal vaccines go directly into the mucosal tissue where infection begins – for example, intranasally or via tablets. If they could induce strong enough mucosal immunity, such vaccines could reduce the risk of infection and transmission. That’s often called “sterilizing” immunity.

Development of these vaccines has just received a massive boost. A global consortium is being funded to develop and then run human challenge trials of intranasal or inhaled vaccines in a program called MusiCC. A human challenge trial – where participants are quarantined and deliberately infected in that controlled environment – could find out quickly and definitively establish whether or not particular vaccines can prevent infection and transmission. If very effective vaccines are tested in this program, it would vault them rapidly through development stages that could otherwise take years.

As well, the US Government’s Project NextGen is calling for interest in developing and/or supporting oral Covid vaccines. This pair of new initiatives kick off this month’s update.

There is also some news from clinical trials for 2 intranasal vaccines, as well as development news on 2 vaccines in the “variant-proof” category, and several preclinical studies.

The race for next generation vaccines is steadily heating up now. And this month, we’ve passed a major milestone: The first data suggesting that an already-authorized nextgen vaccine could outperform the BNT/Pfizer vaccine – with its manufacturers ramping up production facilities for potentially wide distribution in the next year or so.

Most vaccines that reach first-in-human trials don’t make it all the way to major regulator approval. The odds improve, though, for those that make it to mid-stage trials (phase 2). On top of that, there’s a lot of variation in effectiveness between vaccines – so a good range of approaches reaching that mid-stage increases the odds of having much better vaccines.

Though it’s not going at the blistering pace of the early pandemic, the scene is encouraging now. The number of next generation vaccines moving past first-in-human trials is into double digits. With another 2 pancoronavirus vaccines starting clinical trials this month, there’s even a handful of vaccines reaching the early stage at least in this tough category. And the body of clinical evidence seems to be growing steadily, too: We’ve been getting at least some results for an average of 2 clinical trials a month for the last 6 months.

It’s still early days in many ways, though. Even for late-stage trials, most of the efficacy data is for signs of immunity only. We don’t know critical things, especially whether or not there will be mucosal vaccines that can make a major – and lasting – impact on getting and transmitting infection in people. But at least it looks as though more durable boosters are on the horizon.

There’s a lot to get to this month for all types of vaccines, including news from clinical trials for 3 vaccines. This update starts with news from Project NextGen, with funding for another mini-efficacy trial for a mucosal vaccine. After that, I have recent results broken down into 3 categories of next-generation Covid vaccines (definitions below).

In this News Brief we are joined by friend of the show, Maximillian Alvarez of The Real News, to discuss Democrats' pathetic, myopic, and nihilistic attempt to play the Racist Reverse Uno Card on Congressional Republicans.

I warned you

What I did:

Tried embedding the image from this post on Hexbear: ![mlk](https://assets.toots.matapacos.dog/media_attachments/files/111/763/957/392/019/212/original/47924c95b739cd61.png)

Expected result:

Image is embedded

Actual result:

More info: These hosts are whitelisted for embedding images on Hexbear:

• chapo.chat
• discuss.tchncs.de
• hexbear.net
• i.imgur.com
• jlai.lu
• lemm.ee
• lemmy.ml
• lemmy.world
• lemmygrad.ml
• mander.xyz
• pathfinder.social
• possumpat.io
• test.hexbear.net
• toots.matapacos.dog
• ttrpg.network
• www.hexbear.net

But in the case of toots.matapacos.dog, assets.toots.matapacos.dog should be whitelisted instead.

Interview starts at 4:08:02 in the VOD

Context: Media is putting out articles like

https://www.vice.com/en_us/article/epv74k/everything-we-know-about-timhouthi-chalamet-the-yemeni-influencer-celebrating-red-sea-ship-raids , so Hasan talked to him directly

Important: Hasan asks if he knows what One Piece is https://clips.twitch.tv/ExcitedSparklyRamenWoofer-Kdnimydpec0yxUYR